// App-Quantinova.ai

POS0317 (2021) : THE PERFORMANCE OF DIFFUSING CAPACITY FOR MONOXIDE CARBON (DLCO) AND FORCED VITAL CAPACITY (FVC) IN PREDICTING THE ONSET OF SYSTEMIC SCLEROSIS (SSc)-INTERSTITIAL LUNG DISEASE (ILD) IN THE EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) DATABASE

Researchers

Presenter

  • G. Lepri

Principal Investigators

  • L. Tofani

  • A. Moggi Pignone

  • M. Orlandi

  • M. Hughes

  • F. Del Galdo

  • R. Irace

  • O. Distler

  • V. Riccieri

  • Y. Allanore

  • A. M. Gheorghiu

  • E. Siegert

  • J. De Vries-Bouwstra

  • E. Hachulla

  • M. Tikly

  • N. Damjanov

  • F. Spertini

  • L. Mouthon

  • A. M. Hoffmann-Vold

  • A. Gabrielli

  • S. Guiducci

  • M. Matucci-Cerinic

  • D. Furst

  • S. Bellando Randone

Medical Centers

  • AOU Careggi, University of Florence, Hematology, Florence, Italy

  • AOU Careggi, University of Florence, Division of Internal Medicine, Florence, Italy

  • AOU Careggi, University of Florence, Interventional Pulmonology Unit, Florence, Italy

  • Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Department of Rheumatology, Sheffield, United Kingdom

  • NIHR Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Raynaud’s and Scleroderma Programme, Leeds, United Kingdom

  • University of Campania “L. Vanvitelli”, Rheumatology Unit, Department of Precision Medicine, Naples, Italy

  • University Hospital Zürich, University of Zurich, Rheumatology, Zürich, Switzerland

  • Rheumatology Unit, Sapienza University of Rome, Rome, Italy

  • Hopital Cochin, University of Paris, Rheumatology Department, Paris, France

  • Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Internal Medicine & Rheumatology Department, Bucharest, Romania

  • Charite University Hospital, Department of Rheumatology, Berlin, Germany

  • Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden, Netherlands

  • Centre Hospitalier Universitaire, Service de Médecine Interne, Lille, France

  • Chris Hani Baragwanath Academic Hospital University of the Witwatersrand, Division of Rheumatology, Department of Internal Medicine, Johannesburg, South Africa

  • University Belgrade Medical School, Institute of Rheumatology, Belgrade, Serbia

  • CHUV, 16. Service Immunologie et Allergie, Lausanne, Switzerland

  • National Referral Center for Rare Systemic Autoimmune Diseases, Hopital Cochin, APHP, Universite Paris Descartes, Paris, France

  • Oslo University Hospital, Department of Pathology, Oslo, Norway

  • Università Politecnica delle Marche, Department of Clinical and Molecular Sciences (DISCLIMO), Ancona, Italy

  • University of California Medical Center, Rheumatology, Los Angeles, California, United States of America

Locations

  • Italy

  • United Kingdom

  • Switzerland

  • France

  • Romania

  • Germany

  • Netherlands

  • South Africa

  • Serbia

  • Norway

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

Disease

  • Interstitial lung disease

  • Pulmonary arterial hypertension

  • Scleroderma

  • Hypertension

  • Raynaud syndrome

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Acetelion

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved